2026 Guidelines for the Treatment of Axial Spondyloarthritis
ACR
Recent News
Read ArticleNew and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults, alongside a newly developed companion guideline focused specifically on juvenile axial spondyloarthritis.
EULAR26: Updates in SLE and APS
EurekAlert!
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
Read Article
B cell Targeting in SLE
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ
Dr. John Cush @RheumNow ( View Tweet)
RHEUM SURVEY> Do you prefer a lupus drug if it has a lupus nephritis indication (when your treating non-renal SLE)? Answer here >> https://t.co/1KridYM9n8 https://t.co/zIqNB5Mc0O
Dr. John Cush @RheumNow ( View Tweet)
NEJM on anti-CD19 CAR-T cell therapy in B cell lymphoma - 38 pts w/ refractory NHL (24 lg B-cell, 1414 follicular lymphoma) Rx w/ CTL019. 10-yr survival = 32% w/ large B-cell & 47w/ follicular lymphoma; Persistent neutropenia 5%, & 2nd primary cancer seen in 21%. B-cell aplasia https://t.co/CPKvunGZxl
Dr. John Cush @RheumNow ( View Tweet)
Self-Directed Cognitive Behavioral Therapy for Chronic Pain
Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?
EULAR26: Pitfalls in Treat-to-Target
EurekAlert!
Real-world or observational data from registries, claims datasets, or electronic health records can enable us to perform large-scale analyses.
Read Article
Redefining axial spondyloarthritis
An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."
https://t.co/C1Kei8AU3h https://t.co/lspQYyEFHa
Dr. John Cush @RheumNow ( View Tweet)
U Maryland study found that 5-minutes of proximal intercessory prayer (PIP) — in-person prayer offered by a trained volunteer — significantly reduced pain and anxiety in primary care patients compared to a music control group. 180 pain pts (pain >4/10) w/ > 2 pt reductions at 2 & https://t.co/k4JiQvyC31
Dr. John Cush @RheumNow ( View Tweet)
Up to 80% of Brucellosis has MSK Sxs (half in the spine/SI). CDC reports in the USA 2010–2024 1,796 confirmed and probable cases - 61% reported travel (80% Intl travel). Most exposures consumed unpasteurized dairy products or undercooked meat 73%], 62% had animal contact and 40% https://t.co/Njpf71jwKd
Dr. John Cush @RheumNow ( View Tweet)
4-week, proof-of-concept, PBO-controlled RCT Rx 30 Depression pts w/ either PBO or tocilizumab. No improvement by day 14, but over time TCZ pts improved depressive Sxs & severity, fatigue, anxiety, & QOL. Remission seen in 54% vs 31%, favoring TCZ. https://t.co/FpdZJikf8C https://t.co/IaKP3JXARa
Dr. John Cush @RheumNow ( View Tweet)
Redefining axial spondyloarthritis
An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."
https://t.co/6uLv16aOcX https://t.co/a3NxMdnI9F
Dr. John Cush @RheumNow ( View Tweet)
RHEUMATOLOGIST POLL> ?How valuable is a Lupus Nephritis Indication when treating NON-RENAL lupus? Answer here>> https://t.co/K4aikzZRmY https://t.co/60wM3XJE8n
Dr. John Cush @RheumNow ( View Tweet)
No Fetal Risks with First Trimester NSAID Use
PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital https://t.co/ZVUOizbcdg
Dr. John Cush @RheumNow ( View Tweet)
Steroids in SpA? DBRPCT of 94 (nonPsA) SpA pts w/ peripheral arthritis (SJC ≥ 2) placebo or steroids (GC) (csDMARDs background allowed). 76% male, age 32 yrs, TJC 10, SJC 3.6. Wk 24 there was no signif diff betw groups for ACR 50, ACR70 or PSpARC outcomes. https://t.co/snJovW31Uk
Dr. John Cush @RheumNow ( View Tweet)
Retrospective study of 116 BL KOA (Kellgren–Lawrence I–II) pts rx w/ three PRP injx (n 58) or NSAIDs +/- IAhyaluronic acid (n 58). After 5 yrs there was no signif. difference in VAS, WOMAC, and SF-36, with both groups worsening. https://t.co/KDSMTvEl59 https://t.co/lgHOsppIU3
Dr. John Cush @RheumNow ( View Tweet)
Mentors & Mentees can do great things!!! https://t.co/gdf5laCuCm
Dr. John Cush @RheumNow ( View Tweet)
Chinese study of 341 RA pts, half managed post D/C w/ nurse led AI interactive platform vs usual care. @ 6 mos AI platform group had signif better outcomes - DAS28 (-0.77 vs -0.27), HAQ functional status, medication adherence (90 vs 80%), and pt satisfaction (96 vs 76%) https://t.co/SrDgUuAWB3
Dr. John Cush @RheumNow ( View Tweet)
Korean insurance claims study of 50 600 adults w/ newly dx #RA - Persistent low-income significantly increased mortality risk, especially if RA <65 yrs or rural residence; Sustained high-income status provided a protective effect across all age group https://t.co/OIhvz489Ar https://t.co/lYwgc2Ty3n
Dr. John Cush @RheumNow ( View Tweet)
JAMA Review on Low Back Pain
A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the https://t.co/liEitQ2ACf
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Do You Zoster Vaccinate? (6.19.2026)
RheumNow EULAR 2026 Rheumatology Round Up
EULAR 2026 RA Topic Panel
CAR-T Topic Panel EULAR 2026
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
